|
What’s Inside: Visit Us at BioJapan; Early Bird Rates for 2024 Global Partnering and Investor Conference; RayzeBio Closes $358M IPO; Our New Comprehensive Digest for Drug Price Negotiation Program; and more.
|
We’re championing the progress made by California’s life science community and want to hear about your company’s latest scientific breakthrough, investment milestone, or commitment to creating positive change for our industry. Submit your story here for possible inclusion in an upcoming issue. |
|
|
What’s Happening at Biocom California
|
|
Meet Us in Yokohama for BioJapan
Biocom California is proud to once again join BioJapan, Asia’s largest partnering event, taking place in Pacifico Yokohama from October 11–13. Consisting of three separate exhibitions, BioJapan invites companies and top researchers to provide the latest information on cutting-edge technology and industry trends, while also enabling one-on-one meetings to strengthen collaboration, explore business negotiations, and discover new partnerships. Come visit us at the Biocom California Pavilion (Booth D-65) along with our members: NF Techno Commerce Co., Algomedix, Illumina, Neuroservices Alliance, Shanghai Pharma Biotherapeutics USA, and xCARE.
|
|
Global Life Science Partnering and Investor Conference 2024
Our highly anticipated Global Life Science Partnering and Investor Conference will return to the Lodge at Torrey Pines on February 27–29, serving as a pivotal convergence point for renowned life science investors and deal makers from around the world. Given the overwhelming demand in previous years, we encourage prospective attendees to secure your spot and take advantage of early bird pricing, available until this Friday. This annual event provides a dynamic platform for one-on-one partnering meetings, fostering collaboration and exploration of groundbreaking business opportunities. Additionally, it serves as a beacon for industry thought leadership with panels addressing the latest trends in life science investing and partnering.
|
|
|
Industry Intelligence & Member Moments
|
- Arcutis announced positive results from its INTEGUMENT-PED Phase 2 trial of roflumilast cream for the treatment of atopic dermatitis in children.
- Atara Biotherapeutics announced its plans to submit tab-cel BLA, its allogeneic T-cell immunotherapy for Epstein-Barr virus, in Q2 2024 for FDA approval.
- Azzur Group appoints Sarah Stevens to president of Azzur Labs and Azzur Cleanrooms on Demand.
- Bayer and Hologic are teaming up to offer improved mammography scans using contrast-enhanced mammography, or CEM.
- Institute for Myeloma & Bone Cancer Research announced the publication in Targeted Oncology on the survival of 161 unselected, new patients with multiple myeloma.
- Kyverna Therapeutics and Oxford Biomedica signed a license and supply agreement for the LentiVector platform, the first commercially approved lentiviral-based gene delivery system.
- Novo Nordisk offered $60 million for a collaboration with Valo to leverage its AI-powered Opal platform and advance drug discovery and development.
- RayzeBio closed a $358 million initial public offering and full exercise of underwriters’ option of purchase additional shares.
- Regulus Therapeutics shared positive topline data from the first cohort of patients in its Phase 1b clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease.
- Sapien Biosciences has partnered with Thermo Fisher to sequence a thousand of its 75,000+ cancer specimens in the hotspot OncoMineDx NGS panel which covers single mutations of SNVs, fusions and copy number variants.
- Spinogenix was awarded a grant for nearly $1 million from the U.S. Department of Defense’s Congressionally Directed Medical Research Programs for development of its lead clinical candidate, SPG302, a new potential regenerative treatment for Amyotrophic Lateral Sclerosis (ALS).
- UC Irvine received a $2.4 million grant to study the potential treatment for cancer-related cognitive impairment.
- UC San Diego received $17.5 million from the CDC to a group of researchers to strengthen the response to disease outbreaks.
- Vir Technology dosed its first patient in a new Phase 1 trial evaluating VIR-1368, an investigational T-cell vaccine for the prevention of HIV.
|
|
Biocom California Explains Drug Price Setting Process in New Digest
Biocom California has developed a comprehensive digest of the Medicare Drug Price Negotiation Program (MDPNP) for Initial Applicability Year 2026 to help our members understand the requirements, parameters, and timeline of the new policy. The MDPNP was created by the Inflation Reduction Act which requires Medicare to set prices for certain high expenditure drugs without generic or biosimilar competition.
|
|
California Lawmakers Vote as 2023 Legislative Session Ends
California lawmakers voted on hundreds of bills this legislative session, concluding in a late-night session on September 14, 2023. The Los Angeles Times compiled several articles that explain the most interesting or consequential bills that lawmakers have sent to Gov. Gavin Newsom. He has until October 14 to decide which ones will become California law.
|
|
San Diego Housing Efforts Update
There are multiple housing efforts moving throughout the region, each working to bring more housing options to residents. The City of San Diego has been chosen to join a pilot program with ten other cities to provide and share data on best practices to increase housing access and affordability. The city’s Land Use & Housing Committee recently voted to support the Mayor’s Housing Action Package 2.0 with an amendment to continue waiving Development Impact Fees (DIF) for micro units until January 1, 2025. In La Jolla, UC San Diego’s Chancellor Pradeep Khosla is considering building a village near Interstate 5 that would house 5,000 to 6,000 students and cost more than $1 billion.
|
|
LA City Life Science Motion Moves to City Council for Approval
Biocom California policy staff was on hand to speak in support of a proposal we worked on with Los Angeles Councilmember John Lee at the city’s Budget, Finance, and Innovation Committee on September 13. The motion (item No. 15) by Councilmembers Lee and Blumenfield would direct the city to study land use and taxation incentives specific to life science. The item passed committee on consent and will move to city council for formal approval.
|
|
LA County Announces First Ever Life Science Liaison
Biocom California is proud to announce that following our work with Supervisor Holly Mitchell and the Department of Economic Opportunity, LA County has announced the appointment of Melissa Reyes as its first ever “Life Sciences Liaison.” To connect with Melissa or to learn more, email or call (213) 974-6411.
|
|
Roadmap to San Francisco’s Future Progress Update
Since Mayor London Breed put forward five key priorities aimed at revitalizing Downtown San Francisco six months ago, she now reports significant progress has been made. The August report outlines steps that have been taken in nine strategy areas to improve downtown in response to economic changes caused by the pandemic.
|
|
Biocom California
For over 28 years, Biocom California has helped move the life science industry forward with transformative resources that enable companies to make meaningful connections. With a membership base of over {{{dynamic_content_1600}}} companies, we connect our members to each other so they can collaborate and work stronger and smarter together. We connect organizations to capital investment and purchasing solutions so they can grow faster and work more efficiently. We’re their link to advocacy that fights for innovation and we provide an environment where their business and talent can thrive. Biocom California is how the life science industry gets connected.
|
|
|
